Study Summary
This trial is for a new, less-intense cross-linking treatment for people with progressive keratoconus who can't comply with the current, more-intense treatment procedures required by clinical trials.
- Progressive Keratoconus
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 3 Month
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Corneal collagen cross-linking with riboflavin and UVA light
1 of 1
Experimental Treatment
7 Total Participants · 1 Treatment Group
Primary Treatment: Corneal collagen cross-linking with riboflavin/UVA light · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 6 - 18 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Missouri | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Why did patients apply to this trial?
- "I have progressive KC in both eyes treated left in 2018 and needing treatment in right after condition worsening. Ideally help can keep me from further issues and help others dealing with my illness."
How many prior treatments have patients received?
| 1 | 100.0% |
Frequently Asked Questions
Has the FDA authorized Corneal collagen cross-linking with riboflavin/UVA light for use?
"The safety of cross-linking corneal collagen with riboflavin and UVA light has been assessed at a 2 on the scale from 1 to 3. This is due to there being preliminary data supporting safety but not yet any evidence for efficacy in clinical trials." - Anonymous Online Contributor
Is the eligibility criterion for this research restricted to adults over twenty?
"Per this clinical trial's requirements, minors aged 6 to 18 can be enrolled." - Anonymous Online Contributor
What particular demographic would be most appropriate for this investigation?
"The criteria for enrollment into this trial stipulates that patients must have a diagnosis of progressive [keratoconus](https://www.withpower.com/clinical-trials/keratoconus) and be within the age range 6 to 18. Only 7 individuals will ultimately qualify for inclusion." - Anonymous Online Contributor